[1] WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60(6):2099. doi: 10.1002/hep.v60.6
[2] LIANG TJ, BLOCK TM, MCMAHON BJ, et al.Present and future therapies of hepatitis B:from discovery to cure[J].Hepatology, 2015, 62(6):1893. doi: 10.1002/hep.28025
[3] 王贵强, 王福生, 成军, 等.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志, 2015, 31(12):1941. doi: 10.3969/j.issn.1001-5256.2015.12.002
[4] 陈嵬, 吴峰, 窦晓光, 等.慢性HBV感染者肝脏HBV cccDNA含量相关因素分析[J].临床肝胆病杂志, 2013, 29(6):434. doi: 10.3969/j.issn.1001-5256.2013.06.011
[5] MAYNARD M, PARVAZ P, DURANTEL S, et al.Sustained HBs seroconversion during lamivudine and adefovir dipovoxil combination therapy for lamivudine failure[J].Hepatol, 2005, 42(2):279. doi: 10.1016/j.jhep.2004.09.017
[6] BOGLIONE L, CARDELLINO CS, DE NICOLÒ A, et al.Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E[J].J Med Virol, 2014, 86(11):1845. doi: 10.1002/jmv.v86.11
[7] ZENG LY, LIAN JS, CHEN JY, et al.Hepatitis B surface antigen levels during natural history of chronic hepatitis B:a Chinese perspective study[J].World J Gastroenterol, 2014, 20(27):9178.
[8] 钮志林, 朱翔, 沈伟强.干扰素对慢性乙型肝炎病人肝细胞内HBV cccDNA、血清HBsAg、HBV-DNA的影响研究[J].中华医院感染学杂志, 2014, 24(4):792.
[9] 肖作汉, 孟冈, 王立志.HBsAg定量对HBeAg阴性病人PEG-IFN治疗应答的预测[J].肝脏, 2014, 19(12):949. doi: 10.3969/j.issn.1008-1704.2014.12.013
[10] 陶晨, 叶伟, 赵伟.聚乙二醇干扰素对普通干扰素治疗失败慢性乙型肝炎病人的疗效[J].江苏医药, 2012, 38(23):2864.
[11] LI MH, ZHANG L, QU XJ, et al.Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon α-2a treatment[J].Chin Med J (Engl), 2017, 130(5):559. doi: 10.4103/0366-6999.200554
[12] SETO WK, LAM YF, FUNG J, et al.Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment[J].J Gastroenterol Hepatol, 2014, 29(5):1028. doi: 10.1111/jgh.12476
[13] QIU YW, HUANG LH, YANG WL, et al.Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J].Int J Infect Dis, 2016, 43:43. doi: 10.1016/j.ijid.2015.10.019
[14] LIANG Y, JIANG J, SU M, et al.Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy[J].Aliment Pharmacol Ther, 2011, 34(3):344. doi: 10.1111/apt.2011.34.issue-3